5,6-dihydro-5-azacytidine

NSC-264880 refers to 5,6-dihydro-5-azacytidine hydrochloride

Also Known As:

5,6-dihydro-5'-azacytidine; 5,6-dihydro-5-azacytidine hydrochloride; DHAC cpd; NSC 264880; NSC-264880; dihydro-5-azacytidine; 4-amino-5,6-dihydro-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one

Networked: 16 relevant articles (1 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kratzke, Robert A: 2 articles (04/2008 - 11/2002)
2.	Wong, Long: 2 articles (04/2008 - 11/2002)
3.	Cancer and Leukemia Group B: 1 article (04/2008)
4.	Green, Mark R: 1 article (04/2008)
5.	Kern, Jeffrey A: 1 article (04/2008)
6.	Kindler, Hedy L: 1 article (04/2008)
7.	Kratzke, Marian G: 1 article (04/2008)
8.	Vogelzang, Nicholas J: 1 article (04/2008)
9.	Vokes, Everett E: 1 article (04/2008)
10.	Wang, Xiaofei: 1 article (04/2008)

Related Diseases

1.	Malignant Mesothelioma 02/01/1991 - "Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma." 06/01/1997 - "Dihydro-5-azacytidine in malignant mesothelioma. " 06/01/1997 - "In malignant mesothelioma, a disease that is refractory to chemotherapy, dihydro-5-azacytidine has definite antitumor activity. " 06/01/1997 - "Therefore, the objective of this multi-institutional, cooperative group Phase II trial was to determine the efficacy of dihydro-5-azacytidine (DHAC), a pyrimidine analogue, in the treatment of malignant mesothelioma. " 04/15/1998 - "Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B."
2.	Leukemia 04/01/1995 - "Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163." 04/01/2008 - "Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904." 06/01/1981 - "For a comparison of the kinetics of the cytotoxicity of dihydro-5-azacytidine hydrochloride (DHAzaCR) and 5-azacytidine (AzaCR) in L1210 leukemia, the spleen colony assay was used to determine the surviving fraction of normal hematopoietic colony-forming units (NCFU) and leukemia colony-forming units (LCFU). " 04/15/1998 - "In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of patients with advanced, previously untreated mesothelioma, dihydro-5-azacytidine (DHAC) demonstrated a 17% response rate, including 1 complete response, with only mild myelosuppression. " 04/15/1998 - "Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B."
3.	Mesothelioma 11/01/2002 - "In previous clinical trials in mesothelioma, the cytidine analog dihydro-5-azacytidine (DHAC) has been found to induce clinical responses in approximately 17% of patients with mesothelioma treated with this drug, including prolonged complete responses. " 04/01/2008 - "This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16INK4a via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC). " 04/01/2008 - "Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904." 04/15/1998 - "In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of patients with advanced, previously untreated mesothelioma, dihydro-5-azacytidine (DHAC) demonstrated a 17% response rate, including 1 complete response, with only mild myelosuppression. "
4.	Neoplasms (Cancer) 01/01/1985 - "Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor." 01/01/1988 - "Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice." 04/01/2008 - "Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904." 04/15/1998 - "In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of patients with advanced, previously untreated mesothelioma, dihydro-5-azacytidine (DHAC) demonstrated a 17% response rate, including 1 complete response, with only mild myelosuppression. " 04/15/1998 - "Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B."
5.	Melanoma (Melanoma, Malignant) 06/01/1993 - "A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma."

Related Drugs and Biologics

1.	pyrimidine
2.	Azacitidine (5 Azacytidine)
3.	Cytidine
4.	Fetal Hemoglobin (Hemoglobin F)
5.	Cisplatin (Platino)
6.	A 17 (A-17)
7.	DNA (Deoxyribonucleic Acid)
8.	Dihydrotestosterone (Androstanolone)
9.	RNA (Ribonucleic Acid)
10.	Methyltransferases

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)